89bio, Inc. (NASDAQ:ETNB – Get Free Report) has received an average recommendation of “Moderate Buy” from the seven analysts that are presently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation, four have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $30.33.
A number of research firms have issued reports on ETNB. Cantor Fitzgerald restated an “overweight” rating and set a $29.00 target price on shares of 89bio in a research report on Thursday, January 2nd. Raymond James upgraded shares of 89bio to a “strong-buy” rating in a research report on Thursday, December 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 89bio in a research report on Saturday, January 18th. Finally, HC Wainwright reiterated a “buy” rating and issued a $29.00 price target on shares of 89bio in a research report on Tuesday, January 21st.
Read Our Latest Analysis on 89bio
Insider Buying and Selling
Hedge Funds Weigh In On 89bio
Several hedge funds have recently made changes to their positions in the business. Janus Henderson Group PLC grew its stake in shares of 89bio by 14.2% during the 3rd quarter. Janus Henderson Group PLC now owns 15,158,218 shares of the company’s stock worth $112,140,000 after acquiring an additional 1,882,108 shares in the last quarter. Westfield Capital Management Co. LP grew its stake in shares of 89bio by 29.6% in the third quarter. Westfield Capital Management Co. LP now owns 3,006,038 shares of the company’s stock valued at $22,245,000 after buying an additional 686,673 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of 89bio by 8.4% in the third quarter. Geode Capital Management LLC now owns 2,074,970 shares of the company’s stock valued at $15,358,000 after buying an additional 160,356 shares in the last quarter. Erste Asset Management GmbH bought a new position in shares of 89bio in the third quarter valued at $5,631,000. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of 89bio by 8.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 721,050 shares of the company’s stock valued at $5,336,000 after buying an additional 53,932 shares in the last quarter.
89bio Stock Up 0.1 %
Shares of NASDAQ ETNB opened at $9.01 on Friday. The company has a quick ratio of 11.66, a current ratio of 11.66 and a debt-to-equity ratio of 0.09. 89bio has a 12-month low of $5.99 and a 12-month high of $16.63. The company has a market cap of $956.23 million, a price-to-earnings ratio of -3.10 and a beta of 1.14. The firm’s 50-day simple moving average is $7.76 and its 200 day simple moving average is $8.18.
89bio Company Profile
89bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia.
Further Reading
- Five stocks we like better than 89bio
- Breakout Stocks: What They Are and How to Identify Them
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- How Investors Can Find the Best Cheap Dividend Stocks
- What Does the Future Hold for Eli Lilly?
- The Most Important Warren Buffett Stock for Investors: His Own
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for 89bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 89bio and related companies with MarketBeat.com's FREE daily email newsletter.